<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Seattle Genetics, Inc.

    Seattle Genetics, Inc.

    Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...

    Founded 20 years ago, Seattle Genetics was buil...

    Filing Type:    PU
    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...

    Ritter Pharmaceuticals, Inc. develops novel the...

    Filing Type:    PU
    Champions Oncology, Inc.

    Champions Oncology, Inc.

    Champions Oncology, Inc. is engaged in the development of advanced technology solu...

    Champions Oncology, Inc. is engaged in the deve...

    Filing Type:    PU
    VIVUS, Inc.

    VIVUS, Inc.

    With demonstrated clinical development and commercialization expertise, VIVUS is d...

    With demonstrated clinical development and comm...

    Filing Type:    PU
    Rhythm Pharmaceuticals, Inc.

    Rhythm Pharmaceuticals, Inc.

    Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disor...

    Rhythm is a biopharmaceutical company dedicated...

    Filing Type:    PU
    Opiant Pharmaceuticals, Inc.

    Opiant Pharmaceuticals, Inc.

    Opiant is a specialty pharmaceutical company developing medicines for addiction an...

    Opiant is a specialty pharmaceutical company de...

    Filing Type:    PU
    Atossa Genetics Inc.

    Atossa Genetics Inc.

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is...

    Filing Type:    PU
    Morphic Holding, Inc.

    Morphic Holding, Inc.

    Morphic Therapeutic is leading the development of a new generation of oral integri...

    Morphic Therapeutic is leading the development ...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    ©2024 National Investor Network. All Rights Reserved.